Jazz Pharma (JAZZ) Raises FY12 Outlook
Tweet Send to a FriendGet Alerts JAZZ Hot Sheet
Price: $58.36 +0.07%
EPS Growth %: +50.5%
Financial Fact:
Selling, general and administrative: 70.53M
Today's EPS Names:
LBIX, ESEA, ISS, More
EPS Growth %: +50.5%
Financial Fact:
Selling, general and administrative: 70.53M
Today's EPS Names:
LBIX, ESEA, ISS, More
Trade JAZZ Now!
Jazz Pharma (Nasdaq: JAZZ) raised its FY12 EPS guidance to $4.25-$4.40 on sales of $500-$510 million. The Street is currently looking for FY12 EPS of $4.45 on sales of $516.75 million.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Applied Materials, Inc. (AMAT) Tops Q2 EPS by 3c, Offers Guidance
- SciClone (SCLN) Notes Possible Q1 Revenue Impact Due to NovaMed Accounting
- ReneSola Ltd. (SOL) Posts Q1 Loss of 45c/ADS; Guides Q2, FY13 Shipments
Create E-mail Alert Related Categories
Guidance
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
